iBio Inc. Common Stock (IBIO)
Stock · NASDAQ · Health Care
$0.7645as of 10/16/2026
Price chart
Active signals
IBIO Signal Track Record
How signals performed across all stocks →What IBIO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -1.7% | 49% | October 5, 2026 |
| Bollinger Band Breakout | 26 | -6.9% | 35% | August 19, 2026 |
| Bollinger Band Breakdown | 17 | -8.6% | 29% | October 1, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -10.0% | 33% | June 30, 2026 |
| Any 20-session window (baseline) | -5.2% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IBIO
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and A…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 23
- Website
- ibioinc.com/
Fundamentals
- 1-day range
- $0.75$0.8208
- Market cap
- $69.05M
- P/E (trailing)
- —
- P/E (forward)
- -1.27
- EPS (trailing)
- $-0.54
- Dividend yield
- —
- Beta
- 1.42
- Avg. volume
- 723.0K
- Dividend pay date
- June 11, 2018
How iBio Inc. Common Stock Makes Money
Where the revenue actually goes — FY2026 annual results
Source: 10-K filed Aug 28, 2026 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
iBio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IBIOiBio Inc. Common Stock$0.77▼ 1.28%Market cap $69.05MP/E —$0.7328$3.82
- XBITXBiotech Inc. Common Stock$2.12▼ 1.85%Market cap $69.51MP/E —$2.09$3.44
- INOInovio Pharmaceuticals Inc. Common Stock$0.99▼ 4.81%Market cap $69.62MP/E —$0.5632$2.72
- CLNNClene Inc. Common Stock$3.1▼ 6.34%Market cap $68.24MP/E —$3.24$13.5
- CINGCingulate Inc. Common Stock$4.36▼ 0.68%Market cap $68.02MP/E —$3.16$11.89
- RNTXRein Therapeutics Inc. Common Stock$0.59▼ 6.05%Market cap $67.45MP/E —$0.5401$2.18
- CTORCitius Oncology Inc. Common Stock$0.768▲ 2.95%Market cap $70.67MP/E —$0.491$2.25
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IBIO iBio Inc. Common Stock | $69.05M | — | $0.77 | ▼ 1.28% | $0.7328$3.82 |
| XBIT XBiotech Inc. Common Stock | $69.51M | — | $2.12 | ▼ 1.85% | $2.09$3.44 |
| INO Inovio Pharmaceuticals Inc. Common Stock | $69.62M | — | $0.99 | ▼ 4.81% | $0.5632$2.72 |
| CLNN Clene Inc. Common Stock | $68.24M | — | $3.1 | ▼ 6.34% | $3.24$13.5 |
| CING Cingulate Inc. Common Stock | $68.02M | — | $4.36 | ▼ 0.68% | $3.16$11.89 |
| RNTX Rein Therapeutics Inc. Common Stock | $67.45M | — | $0.59 | ▼ 6.05% | $0.5401$2.18 |
| CTOR Citius Oncology Inc. Common Stock | $70.67M | — | $0.768 | ▲ 2.95% | $0.491$2.25 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- iBio Highlights Preclinical Body-Composition Data From Obese NHP Study Evaluating IBIO-610, Activin E Antibody Candidate, Alone And In Combination With Semaglutide, GLP-1 Receptor Agonist Used To Treat Obesitybenzinga · 10/13/2026
- iBio, Inc. (IBIO) Presents at 2026 EASD Annual Meeting - SlideshowSeekingAlpha · 10/7/2026
- This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayBenzinga · 9/17/2026
- HC Wainwright & Co. Initiates Coverage On iBio with Buy Rating, Announces Price Target of $7Benzinga · 9/17/2026
- 12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga · 9/14/2026
Insider Activity
Insider Actions →- Carr Molly · July 31, 2026 · Grant430.0K
- Stoner Elizabeth · May 18, 2026 · Grant60.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 19.22M
- Total value held
- $36.49M
- Institutional holders
- 49
- Unknown3.11M
- Unknown1.95M
- Unknown1.58M
- Unknown1.55M
- Unknown1.30M
- Unknown1.09M
- Unknown1.01M
- Unknown957.1K
- Unknown956.4K
- Unknown904.3K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
iBio to Present Data at 2026 EASD Annual Meeting
iBio Inc. announced it will present at the 2026 EASD Annual Meeting. This event is relevant as it provides a platform to share updates on the company's medical technology. The stock is currently trading near its 52-week low, with an RSI of 24.6 indicating oversold conditions. Analysts maintain an average price target of $5.69, significantly above the current market price.
iBio to Present Data at 2026 EASD Annual Meeting. iBio Inc. announced it will present at the 2026 EASD Annual Meeting. This event is relevant as it provides a platform to share updates on the company's medical technology. The stock is currently trading near its 52-week low, with an RSI of 24.6 indicating oversold conditions. Analysts maintain an average price target of $5.69, significantly above the current market price.